Pfizer India withdraws products from Karnataka after spurious-drugs crackdown
Pfizer India removed affected products from Karnataka markets after counterfeit medicines were found using copied batch details. State regulators cancelled 16 retailer and wholesaler licences and suspended eight, including the company’s Nelamangala depot licence.
What happened
Pfizer India removed affected products from Karnataka after counterfeit drugs copied its batch details. Karnataka authorities cancelled 16 licences and
Key facts
- 16 pharmaceutical retailer and wholesaler licences cancelled
- 8 licences suspended
- Pfizer worked with authorities for one month
What changed
Pfizer India removed affected products from Karnataka after counterfeit drugs copied its batch details. Karnataka authorities cancelled 16 licences and suspended eight, including Pfizer’s Nelamangala depot, during a spurious-drugs investigation.
Why this matters
Immediately audit Karnataka inventory, strengthen batch-level traceability and coordinate with regulators to restore compliant product availability after the withdrawal.
What to watch
- Regulator disclosure of the counterfeit products, therapeutic categories, copied batch numbers, and original source of the spurious stock.
- Whether Pfizer's Nelamangala depot suspension is lifted, extended, or followed by action in other states.
- Additional licence cancellations, police cases, arrests, or links to manufacturers and interstate distribution networks.
- Reports of shortages, prescription substitution, or hospital procurement changes for Pfizer's affected products.
- Any national CDSCO advisory, mandatory recall notice, or expanded track-and-trace requirement for pharmaceutical distribution.